Salehbayat Maryam, Abolfazli Roya, Mohebbi Niayesh, Savar Seyed Mehrdad, Shalviri Gloria, Gholami Kheirollah
School of Pharmacy, International Campus, Tehran University of Medical Sciences, Tehran, Iran.
Department of Neurology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Basic Clin Neurosci. 2023 Nov-Dec;14(6):879-883. doi: 10.32598/bcn.2021.2848.2. Epub 2023 Nov 1.
High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study.
ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy (DMT) for MS during the last three months were investigated.
A total of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious.
The high frequency of adverse drug reactions in this study shows a strong need for strategy planning to increase patients' adherence to treatment.
Adverse drug reactions (ADRs) are common in MS patients using disease modifying therapies.Such ADRs are more common in women than men.Various brand names of biosimilar disease-modifying therapy (DMT)s may have a different ADR profile.
Multiple sclerosis (MS) is a condition that can be managed by using disease modifying medications. Such medication could trigger an adverse reaction in the patients., affecting their commitment to the treatment. By identifying these adverse reactions and educating the MS patients about these reactions and how the adverse effects can be managed, healthcare providers can improve the treatment process. This study recorded the adverse drug reactions in 250 MS patients who were receiving the medication for at least three months. Most of the patients (76.4%) experienced some kind of adverse reaction. A bigger proportion of women experienced adverse reactions than men. About 84% of these reactions occurred within the first 3 hours of receiving the medication. Depending on the medication's brand name, the rate of adverse drug reactions were different in some cases. The results of this study point out the fact that experiencing adverse drug reactions is common in MS patients and these experiences could be different for each medication with a different brand name. Therefore, it is important for the healthcare providers to inform the patients about such reactions and the patients should seek all the information they need to manage these adverse effects by consulting their physician.
药物不良反应（ADR）的高发生率对多发性硬化症（MS）的治疗构成挑战。本研究旨在通过一项观察性横断面研究评估MS药物引起的ADR的性质和发生率。
对在过去三个月内看过神经科医生并接受至少一种MS疾病修正治疗（DMT）的所有门诊患者的ADR进行调查。
在这些患者中共检测到484例ADR。可预防率为5.9%，严重反应占0.61%。
本研究中药物不良反应的高发生率表明迫切需要制定策略计划以提高患者对治疗的依从性。
药物不良反应在使用疾病修正疗法的MS患者中很常见。此类ADR在女性中比在男性中更常见。生物类似疾病修正疗法（DMT）的各种品牌可能有不同的ADR特征。
多发性硬化症（MS）可以通过使用疾病修正药物来控制。此类药物可能会在患者中引发不良反应，影响他们对治疗的坚持。通过识别这些不良反应并对MS患者进行关于这些反应以及如何管理不良反应的教育，医疗保健提供者可以改善治疗过程。本研究记录了250例接受药物治疗至少三个月的MS患者的药物不良反应。大多数患者（76.4%）经历了某种不良反应。经历不良反应的女性比例高于男性。这些反应中约84%发生在服药后的前3小时内。根据药物的品牌，在某些情况下药物不良反应的发生率有所不同。本研究结果指出，药物不良反应在MS患者中很常见，并且每种不同品牌药物的不良反应情况可能不同。因此，医疗保健提供者向患者告知此类反应非常重要，患者应通过咨询医生获取管理这些不良反应所需的所有信息。
